NeuroBo Pharmaceuticals (NRBO) Institutional Ownership $0.64 0.00 (0.00%) As of 08/15/2025 Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for NeuroBo Pharmaceuticals (NASDAQ:NRBO)CurrentInstitutional OwnershipPercentage1.37%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$49.67KNumber ofInstitutional Sellers(last 12 months)0 Get NRBO Insider Trade Alerts Want to know when executives and insiders are buying or selling NeuroBo Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data NRBO Institutional Buying and Selling by Quarter NeuroBo Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/6/2024 Ferguson Wellman Capital Management Inc.15,670$50K0.0%N/A0.191% 8/15/2024 Armistice Capital LLC696,829$3.37M0.0%N/A14.204% 8/15/2024 Affinity Asset Advisors LLC89,222$432K0.0%N/A1.819% 2/14/2022 Murchinson Ltd.205,256$251K0.0%N/A0.772% 11/9/2021BlackRock Inc.44,579$166K0.0%-11.3%0.200% 9/3/2021Parametric Portfolio Associates LLC16,530$55K0.0%N/A0.074% 8/16/2021 State Street Corp15,878$53K0.0%-78.6%0.071% 8/13/2021 Northern Trust Corp24,579$82K0.0%-68.9%0.110% 8/13/2021 Vanguard Group Inc.477,918$1.59M0.0%-30.2%2.145% 8/12/2021Advisory Services Network LLC8,550$28K0.0%N/A0.038% 8/12/2021Ergoteles LLC30,800$103K0.0%N/A0.138% 8/11/2021 Deutsche Bank AG31,090$104K0.0%+1,016.3%0.140% 8/4/2021 Mount Yale Investment Advisors LLC57,425$191K0.0%N/A0.258% 5/17/2021 Goldman Sachs Group Inc.10,056$44K0.0%N/A0.045% (Data available from 1/1/2016 forward) NRBO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NRBO shares? During the previous two years, the following institutional investors and hedge funds held shares of NeuroBo Pharmaceuticals shares: Armistice Capital LLC ($3.37M), and Affinity Asset Advisors LLC ($432K), Ferguson Wellman Capital Management Inc. ($50K).Learn more on NeuroBo Pharmaceuticals' institutional investors. What percentage of NeuroBo Pharmaceuticals' stock is owned by institutional investors? 1.37% of NeuroBo Pharmaceuticals' stock is owned by institutional investors. Learn more on NRBO's institutional investor holdings. Which institutional investors have been buying NeuroBo Pharmaceuticals' stock? The following institutional investors have purchased NeuroBo Pharmaceuticals' stock in the last 24 months: Armistice Capital LLC ($696.83K), Affinity Asset Advisors LLC ($89.22K), and Ferguson Wellman Capital Management Inc. ($15.67K). How much institutional buying is happening at NeuroBo Pharmaceuticals? Institutional investors have bought a total of 15,670 shares in the last 24 months. This purchase volume represents approximately $49.67K in transactions. Related Companies BTC Digital Major Shareholders Sphere 3D Major Shareholders Netcapital Major Shareholders Glen Burnie Bancorp Major Shareholders Carver Bancorp Major Shareholders LM Funding America Major Shareholders Mawson Infrastructure Group Major Shareholders Soluna Major Shareholders SOS Major Shareholders SHF Major Shareholders This page (NASDAQ:NRBO) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access